Skip to main content

Table 2 Multivariable survival analysis for the immunohistochemical membrane EGFR staining

From: Biological and clinical impact of membrane EGFR expression in a subgroup of OC patients from the phase IV ovarian cancer MITO-16A/MANGO-OV2A trial

 

PFS

OS

HR

(95% CI)

P value

HR

(95% CI)

P-valuea

EGFR

 M0

1

  

1

  

 M

0.9

(0.69–1.19)

0.47

0.92

(0.61–1.38)

0.68

 MM

1.79

(0.95–3.36)

0.07

2.84

(1.18–6.83)

0.019

Age

  < 65y

1

  

1

  

  ≥ 65y

0.89

(0.65–1.21)

0.45

0.79

(0.51–1.24)

0.31

ECOG PS

 0

1

  

1

  

 1–2

1.47

(1.05–2.06)

0.02

1.91

(1.19–3.06)

0.0075

FIGO stage

 IIIB-IIIC

1

  

1

  

 IV

2.17

(1.57–3)

 < 0.0001

1.81

(1.14–2.88)

0.011

Residual disease

 None

1

  

1

  

  ≤ 1 cm

1.47

(1.02–2.1)

0.037

1.61

(0.92–2.84)

0.09

  > 1 cm

1.87

(1.34–2.63)

0.0003

2.14

(1.3–3.55)

0.003

 No surgery

3.23

(1.88–5.52)

 < 0.0001

2.97

(1.41–6.26)

0.0043

Tumor histology

 HGSOC

1

  

1

  

 Other

1.28

(0.87–1.88)

0.21

1.17

(0.67–2.03)

0.59

  1. aIn bold are significant p value from Cox multivariable analysis